Oramed Pharmaceuticals Inc. financial data

Symbol
ORMP on Nasdaq
Location
1185 Avenue Of The Americas, 3 Rd Floor, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.56K % +547%
Return On Equity -16.3 % -230%
Return On Assets -15.4 % -258%
Operating Margin -1.01K % +30.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 41M shares +0.58%
Common Stock, Shares, Outstanding 40.8M shares +0.53%
Entity Public Float 131M USD +0.51%
Common Stock, Value, Issued 491K USD +0.62%
Weighted Average Number of Shares Outstanding, Basic 41.7M shares +1.91%
Weighted Average Number of Shares Outstanding, Diluted 42.6M shares +2.45%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2M USD
Cost of Revenue 1.99M USD
Research and Development Expense 6.94M USD +29.9%
Selling and Marketing Expense -663K USD -243%
General and Administrative Expense 6.74M USD -17.6%
Operating Income (Loss) -13.7M USD -6.26%
Nonoperating Income (Expense) -8.8M USD -123%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -22.2M USD +21.2%
Income Tax Expense (Benefit) -126K USD -108%
Net Income (Loss) Attributable to Parent -24.2M USD -219%
Earnings Per Share, Basic 0 USD/shares -220%
Earnings Per Share, Diluted 0 USD/shares -222%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 15.8M USD
Marketable Securities, Current 1.75M USD -25.2%
Assets, Current 99M USD -35.4%
Other Long-term Investments 7.16M USD
Property, Plant and Equipment, Net 645K USD -15.7%
Operating Lease, Right-of-Use Asset 882K USD +55.8%
Other Assets, Noncurrent 38K USD
Assets 162M USD -12.2%
Accounts Payable, Current 715K USD
Employee-related Liabilities, Current 259K USD
Accrued Liabilities, Current 841K USD
Liabilities, Current 3.69M USD -1.07%
Contract with Customer, Liability, Noncurrent 2M USD -50%
Operating Lease, Liability, Noncurrent 648K USD +175%
Other Liabilities, Noncurrent 60K USD -4.76%
Retained Earnings (Accumulated Deficit) -171M USD -16.5%
Stockholders' Equity Attributable to Parent 155M USD -12.7%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 154M USD -12.8%
Liabilities and Equity 162M USD -12.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.52M USD -138%
Net Cash Provided by (Used in) Financing Activities -19M USD -882%
Net Cash Provided by (Used in) Investing Activities 23.6M USD -21.3%
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 40.8M shares +0.53%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 20.1M USD +111%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 15.8M USD -81.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 571K USD
Deferred Tax Assets, Valuation Allowance 36.1M USD +26.9%
Operating Lease, Liability 912K USD +87.7%
Depreciation 30K USD -46.4%
Payments to Acquire Property, Plant, and Equipment 3K USD +50%
Lessee, Operating Lease, Liability, to be Paid 954K USD +88.9%
Operating Lease, Liability, Current 264K USD +5.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 162K USD +18.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 296K USD +35.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 42K USD +121%
Lessee, Operating Lease, Liability, to be Paid, Year Three 134K USD +644%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD -3.46%
Unrecognized Tax Benefits 11K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 129K USD
Additional Paid in Capital 319M USD +5.99%
Interest Expense 592K USD